<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02529865</url>
  </required_header>
  <id_info>
    <org_study_id>CAMCR-005</org_study_id>
    <secondary_id>UMIN000017901</secondary_id>
    <nct_id>NCT02529865</nct_id>
  </id_info>
  <brief_title>Clinical Trial of Autologous Adipose Derived Regenerative Cells for the Treatment of Male Stress Urinary Incontinence</brief_title>
  <acronym>ADRESU</acronym>
  <official_title>Open-label, Multi-center, Single Arm Study to Evaluate the Efficacy and Safety of Periurethral Injection of Autologous Adipose Derived Regenerative Cells (ADRCs) for the Treatment of Male Stress Urinary Incontinence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nagoya University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nagoya University</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of periurethral injection of
      autologous Adipose Derived Regenerative Cells (ADRCs) in male stress urinary incontinence.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 29, 2015</start_date>
  <completion_date type="Anticipated">March 2019</completion_date>
  <primary_completion_date type="Anticipated">March 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of patients with improvement in urine leakage volume as greater than 50% reduction from baseline by 24-hour pad test</measure>
    <time_frame>Baseline and 52 weeks (LOCF) after intervention</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of patients with improvement in urine leakage volume as greater than 50% reduction from baseline by 24-hour pad test</measure>
    <time_frame>Baseline, 2, 4, 12, 26, 38 and 52 weeks after intervention</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urine leakage volume by 24-hour pad test</measure>
    <time_frame>Baseline, 2, 4, 12, 26, 38 and 52 weeks after intervention</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of patients with improvement in the number of incontinence episodes per day as greater than 50% reduction from baseline</measure>
    <time_frame>Baseline, 2, 4, 12, 26, 38 and 52 weeks after intervention</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of incontinence episodes per day</measure>
    <time_frame>Baseline, 2, 4, 12, 26, 38 and 52 weeks after intervention</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of pads used per day</measure>
    <time_frame>Baseline, 2, 4, 12, 26, 38 and 52 weeks after intervention</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QOL score (ICIQ-SF and KHQ)</measure>
    <time_frame>Baseline, 26 and 52 weeks after intervention</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient overall satisfaction</measure>
    <time_frame>Baseline, 26 and 52 weeks after intervention</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urodynamic parameters (MUCP, FPL and ALPP)</measure>
    <time_frame>Baseline, 2, 4, 12, 26 and 52 weeks after intervention</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood flow at the injection site measured by transrectal ultrasonography</measure>
    <time_frame>Baseline,12, 26 and 52 weeks after intervention</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Injection site evaluated by pelvis MRI scan</measure>
    <time_frame>Baseline, 2, 26 and 52 weeks after intervention</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>Urinary Incontinence , Stress</condition>
  <arm_group>
    <arm_group_label>ADRCs and Adipose tissue</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Periurethral injection of autologous adipose derived regenerative cells and adipose tissue</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Periurethral injection of autologous ADRCs and adipose tissue</intervention_name>
    <description>1 mL of the isolated ADRC is injected into the region of the external urethral sphincter, and another 4 mL of the ADRC and 16mL autologous adipose cells is injected under the urethral mucosa.</description>
    <arm_group_label>ADRCs and Adipose tissue</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males with stress urinary incontinence with insufficient effect by behavioral therapy
             or pharmacotherapy persisting more than 1 year after either of the following surgical
             procedure:

               -  Patients with symptoms after radical prostatectomy for localized prostate cancer
                  and currently without relapse/metastasis, and PSA level less than 0.1 ng/mL for
                  over 1 year

               -  Patients with symptoms after transurethral prostatectomy or laser prostatectomy
                  for prostatic hyperplasia, and PSA level less than 4.0 ng/mL over 1 year

          -  Age of 20 or above

          -  Mild to moderate urinary incontinence on the 24-hour pad test

          -  Patients who can keep a bladder diary in a satisfactory manner

          -  Patients who are willing and able to give signed consent

        Exclusion Criteria:

          -  - Concurrent with any other types of urinary incontinence

          -  History of urinary or reproductive surgery within 6 months

          -  History of behavioral therapy or pharmacotherapy within 3 months

          -  Concurrent with diabetes insipidus

          -  History of radiotherapy in the lower urinary tract

          -  History of ADRCs treatment for stress urinary incontinence

          -  History of any type of cell therapy within 6 months

          -  Participation in any other clinical trial within 3 months

          -  Concurrent with lower urinary tract obstruction

          -  Concurrent with urolithiasis, urinary tract infection or interstitial cystitis

          -  History of recurrent urinary tract infection

          -  History of malignant neoplasm within 5 years or a suspicion of it

          -  Life expectancy of less than 1 year

          -  Any other patients whom the trial investigator deemed ineligible to this study
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Momokazu Gotoh, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Urology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Nagoya university Hospital</name>
      <address>
        <city>Nagoya</city>
        <state>Aichi</state>
        <zip>466-8560</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanazawa University Hospital</name>
      <address>
        <city>Kanazawa</city>
        <state>Ishikawa</state>
        <zip>920-8641</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shinshu University Hospital</name>
      <address>
        <city>Matsumoto</city>
        <state>Nagano</state>
        <zip>390-8621</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dokkyo Medical University Hospital</name>
      <address>
        <city>Shimotsuga</city>
        <state>Tochigi</state>
        <zip>321-0293</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <reference>
    <citation>Shaw CF 3rd, Isab AA, Coffer MT, Mirabelli CK. Gold(I) efflux from auranofin-treated red blood cells. Evidence for a glutathione-gold-albumin metabolite. Biochem Pharmacol. 1990 Sep 15;40(6):1227-34.</citation>
    <PMID>2403377</PMID>
  </reference>
  <reference>
    <citation>Hersh WR, Greenes RA. Information retrieval in medicine: state of the art. MD Comput. 1990 Sep-Oct;7(5):302-11. Review.</citation>
    <PMID>2243546</PMID>
  </reference>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 18, 2015</study_first_submitted>
  <study_first_submitted_qc>August 18, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 20, 2015</study_first_posted>
  <last_update_submitted>May 10, 2018</last_update_submitted>
  <last_update_submitted_qc>May 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Nagoya University</investigator_affiliation>
    <investigator_full_name>Momokazu Gotoh</investigator_full_name>
    <investigator_title>MD, PhD, Professor at Department of Urology, Nagoya University Hospital</investigator_title>
  </responsible_party>
  <keyword>Cell Transplantation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Incontinence</mesh_term>
    <mesh_term>Enuresis</mesh_term>
    <mesh_term>Urinary Incontinence, Stress</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

